Novo Nordisk has established itself as a leader in the diabetes and obesity treatment markets, with a strong focus on GLP-1 receptor agonists. The company's key products, including Ozempic ...

Novo Nordisk (NYSE:NVO) A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. The repeat offenders received their latest dressing-downs over a gathering of healthcare ...

Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within the increasingly ...

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...

Novo Nordisk has been one of the chief beneficiaries of the boom in GLP-1 drugs, which have shown great promise in fighting obesity. Competition in the space is fierce, but shares got a much ...

The firm said it now plans "further clinical development of amycretin in adults with overweight or obesity." Novo Nordisk Stock Had Been Trending Lower After Disappointing Results Novo Nordisk's U ...

Novo Nordisk shares rose sharply Friday after the ... the price of its drugs in the U.S. The company behind blockbuster obesity treatment Wegovy and diabetes drug Ozempic is busy developing ...